ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

COMPARISON OF THYROID DYSFUNCTION IN CASES OF HEPATITIS C MANAGED WITH INTERFERON ALPHA AND PEGYLATED INTERFERON

Dr. Qurban Hussain, Dr. Jalil Iqbal, Dr. Masud Ali Ansari.

Objectives: To compare the frequency of thyroid disorders in patients of chronic hepatitis C being treated with interferon alpha versus pegylated interferon. Materials & Methods: This randomized Controlled Trial was conducted at Department of Medicine Jinnah Hospital Lahore from January 2018 to June 2018 over the period of 6 months. A total of 340 diagnosed case of chronic hepatitis C by PSR HCV RNA of both genders, having age range between 25 years to 60 years, were included in the study. Results: Total 340 patients with hepatitis C were selected. Mean age of the patients of group A & B was as 35.73 ± 7.31 years and 35.91 ± 8.24 years respectively. Out of these 340 patients, 201 (59.12%) were male and 139 (40.88%) were females with ratio of 2.09:1. Mean thyroid stimulating hormone level was 2.31 ± 1.12 in group A and 2.46 ± 0.98 in group B. Thyroid disorder was seen in 15 (8.82%) patients in conventional interferon therapy group and 31 (18.24%) patients in pegylated interferon therapy group with p-value of 0.011. Conclusion: This study concluded that the frequency of thyroid disorders is lower in patients of chronic hepatitis C being treated with interferon alpha compared to pegylated interferon with higher frequency among females in both groups. Keywords: Hepatitis C, interferon therapy, hypothyroidism, hyperthyroidism.

FULL TEXT